These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 5043819)
1. Molecular size of in vivo liver catalase-depressing substance from rhodamine sarcoma of rat. Matsuo Y; Nishikawa K; Horio T Gan; 1972 Feb; 63(1):95-110. PubMed ID: 5043819 [No Abstract] [Full Text] [Related]
2. Intracellular distribution of in vivo liver catalase-depressing substance in rhodamine sarcoma. Kannan Y; Nishikawa K; Matuo Y; Horio T Gan; 1972 Apr; 63(2):201-8. PubMed ID: 5070238 [No Abstract] [Full Text] [Related]
3. Effects on various types of liver catalase by growth of rhodamine sarcoma and by administration of in vivo catalase-depressing substance prepared from the tumor. Nakamura T; Matuo Y; Nishikawa K; Horio T; Okunuki K Gan; 1968 Aug; 59(4):317-25. PubMed ID: 5707406 [No Abstract] [Full Text] [Related]
4. In vivo liver catalase-depressing substance from rhodamine sarcoma. Matuo Y Gan; 1968 Oct; 59(5):405-13. PubMed ID: 5707975 [No Abstract] [Full Text] [Related]
5. Effect of growth of rhodamine sarcoma in rat on some liver enzyme activities. Matuo Y; Nishikawa K; Horio T; Okunuki K Gan; 1968 Aug; 59(4):299-316. PubMed ID: 4303368 [No Abstract] [Full Text] [Related]
7. Evidence that inhibition of hepatic drug oxidation by tumors is mediated by a circulating humor. Boulos BM; MacDougall M; Shoeman DW; Azarnoff DL Proc Soc Exp Biol Med; 1972 Apr; 139(4):1353-5. PubMed ID: 5023334 [No Abstract] [Full Text] [Related]
9. Immunological studies on in vivo liver catalase-depressing substance. Fukuyama Y; Kurata Y Gan; 1969 Apr; 60(2):199-203. PubMed ID: 4309387 [No Abstract] [Full Text] [Related]
10. Nuclear proteins capable of depressing in vivo liver catalase. Miyazaki K; Nagao Y; Matumoto K; Nishikawa K; Horio T Gan; 1973 Oct; 64(5):449-63. PubMed ID: 4769737 [No Abstract] [Full Text] [Related]
11. Tissue-specific distribution of non-histone proteins in nuclei of various tissues of rats and its change with growth of rhodamine sarcoma. Miyazaki K; Hagiwara H; Nagao Y; Matuo Y; Horio T J Biochem; 1978 Jul; 84(1):135-43. PubMed ID: 690097 [No Abstract] [Full Text] [Related]
12. [Intracellular protein degradation. IV. Isolation and characterization of peptidases from rat liver lysosomes]. Kirschke H; Langner J; Wiederanders B; Ansorge S; Bohley P Acta Biol Med Ger; 1972; 28(2):305-22. PubMed ID: 5052836 [No Abstract] [Full Text] [Related]
13. Biochemical studies on the liver catalase depressing factor of toxohormone. OKAMURA Y Kyushu J Med Sci; 1962 Dec; 13():299-311. PubMed ID: 13939793 [No Abstract] [Full Text] [Related]
14. [DNA distribution in transplanted tumors of the rat]. Grimm I; Grimm D; Weidhase RA; Schindler J Z Gesamte Hyg; 1985 Jun; 31(6):359-62. PubMed ID: 4036199 [No Abstract] [Full Text] [Related]
15. The effects of toxohormone on the ultrastructure of rat hepatocytes. Parry EW; Ghadially FN J Pathol; 1970 Mar; 100(3):161-8. PubMed ID: 5428935 [No Abstract] [Full Text] [Related]
16. Effect of injection of chromatins from rhodamine sarcoma into rats on pI-isozymes of liver pyruvate kinase. Nakamura T; Hosoi K; Nishikawa K; Horio T Gan; 1972 Apr; 63(2):239-50. PubMed ID: 5070239 [No Abstract] [Full Text] [Related]
17. An improved method for the estimation of catalase activity and its application to the study of toxohormone. OKUDA H; BIN ; HAGA ; FUJII S; YAMAMURA Y Gan; 1963 Mar; 54():85-92. PubMed ID: 13939849 [No Abstract] [Full Text] [Related]